Simon Latimer | Head of Investor Relations |
John Higgins | CEO |
Matt Foehr | COO |
Matt Korenberg | CFO |
Larry Solow | CJS Securities |
Matt Hewitt | Craig Hallum Capital |
Good day, everyone. And welcome to the Ligand Pharmaceuticals First Quarter '22 Earnings Call. At this time, all participants are in a listen-only mode [Operator Instructions]. Please note this call maybe recorded. It is now my pleasure to turn today's program over to Simon Latimer, Head of Investor Relations.